HEM Pharma Non-Registered Executive Kim Bong-jun Acquires 6,000 Shares via Stock Option Exercise — Minimal Capital Inflow and Dilution Impact

HEM Pharma Vice President Kim Bong-jun, a non-registered executive, exercised stock options on June 15, 2026 to acquire 6,000 common shares at 14,590 KRW per share.
The exercise brought approximately 87.5 million KRW in capital to the company, increasing total shares by only 0.08%, resulting in negligible dilution.
This routine executive compensation transaction has no material impact on the stock price outlook or governance structure.
[AI Summary]The small-scale stock option exercise by a non-registered executive results in minimal capital inflow and dilution, with no significant effect on shareholder value.